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Abstract The neuropathology of Alzheimer’s disease
(AD) is characterized by the accumulation of amyloid
peptide Ab in the brain derived from proteolytic cleavage
of the amyloid precursor protein (APP). Vaccination of
mice with plasmid DNA coding for the human Ab42
peptide together with low doses of preaggregated pep-
tide induced antibodies with detectable titers after only
2 weeks. One serum was directed against the four amino-
terminal amino acids DAEF and differs from previously
described ones. Both immune sera and monoclonal anti-
bodies solubilized preformed aggregates of Ab42 in vitro
and recognized amyloid plaques in brain sections of mice
transgenic for human APP. Passive immunization of trans-
genic AD mice caused a significant and rapid reduction in
brain amyloid plaques within 24 h. The combined DNA
peptide vaccine may prove useful for active immunization
with few inoculations and low peptide dose which may
prevent the recently described inflammatory reactions in
patients. The monoclonal antibodies are applicable for
passive immunization studies and may lead to a therapy
of AD.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
which is preceded by the deposition of amyloid-b (Ab)
peptides into Ab plaques and brain blood vessel walls [1].
The Ab peptides are 39–43 amino acids in length and
derived from sequential proteolytic cleavage of the am-
yloid precursor protein (APP) [2]. APP is a large mem-
brane protein expressed ubiquitously throughout many
tissues including brain. Ab peptides convert from soluble
molecules to insoluble aggregates in a concentration-de-
pendent manner. These amyloid aggregates are formed
from a soluble, mainly coiled, and slightly a-helical form
and are characterized by a high degree of b-sheets, a
fibrillar morphology in electron microscopy, and the
ability to bind and alter spectroscopic properties of thio-
flavin [3]. Recently evidence has accumulated which
suggests that AD is a synaptic failure due to diffusible
oligomers of amyloid peptides [4].
A mouse model of brain amyloid plaque formation
expresses the human APP gene with a familial AD mu-
tation (APP V717F) under the control of a neuronal
promoter [5]. A mouse model with a transgene expressed
in the pancreas has also been described (NORBA mice)
[6]. Here an AD mouse model was used overexpressing
human APP in the brain of heterozygotic transgenic mice,
with mutations K670N, M671L, the Swedish variant
(HuAPP695SWE) [7]. The transgenic expression of APP
in the brain leads to increased concentrations of Ab42 and
to the formation of amyloid plaques during aging with
disease symptoms detectable as behavioral changes be-
tween 12–18 months of age. At early stages diffuse am-
yloid deposits can be detected in brain sections by im-
munohistochemical analysis or by enzyme-linked immu-
nosorbent assay (ELISA) in brain extracts [7], at later
stages plaques become detectable by dyes such as thio-
flavins or Congo red [3].
Several studies with APP-transgenic mice have dem-
onstrated that active or passive immunization against the
Ab peptide leads to a reduction in amyloid plaque burden
and an improvement in memory impairment [8, 9].
Monoclonal antibodies generated previously were di-
rected against the N-terminal 12–16 residues of the pep-
tide and cross-react with the monomeric peptide [10, 11],
possibly due to the fact that amyloid aggregates exhibit an
exposed unstructured N-terminal region [12]. Conforma-
tional antibodies against the Ab fibrils have also been
reported [13]. Another monoclonal antibody, m266, di-
rected against a central region of Ab (amino acids 13–28)
reduced the amyloid burden of the brain in APP-trans-
genic mice and reversed memory defects [14, 15, 16].
After peripheral injection of m266 plasma levels of Ab
peptide increased rapidly, presumably by facilitating the
efflux of soluble Ab peptide from the brain. Two other
antibodies, AMY-33 and 6F/3D, were raised against Ab
peptides 1–28 and 8–17, respectively, and prevented ag-
gregation in vitro [17]. One antibody is known, 3D6,
which binds to the amino terminal amino acids and
rapidly induced a reduction in amyloid plaque burden in
vivo [18]. Here two commercially available antibodies
4G8 [19] and 6H1 were used as controls. They are di-
rected against the amino acid residues 17–24 and 1–17 of
human and mouse Ab, respectively.
In a previous study antibodies against Ab plaques were
produced by using aggregated Ab42 peptides in conjunc-
tion with Freund’s complete adjuvant at a dose of 100 g
antigen per injection for a total number of 11 immu-
nizations [20]. Five different peptide immunization pro-
cedures have been recently compared [21]. A liposome-
based vaccination has also been described, which caused
a reduction in Ab plaques in the pancreas of transgenic
mice [6]. Peptide immunizations in patients caused in-
flammation in the brain and led to the halt of a clinical
trial [22].
Vaccination with plasmid DNA encoding tumor-asso-
ciated antigens or antigens derived from various patho-
gens leads to the expression and presentation of foreign
antigens over a prolonged period of time at low levels,
inducing both broad humoral and cellular immune re-
sponses (reviewed in [23, 24, 25]). These antigen-specific
immune responses can be further enhanced by boosting
with corresponding peptides, proteins or viral vectors
expressing the antigens [24, 26]. DNA vaccination in-
duces Th1 or Th2 type immune response depending on
the route of injection, amount of DNA, and the nature of
the antigen [27].
In this study we describe an effective vaccination
procedure using plasmid DNA coding for Ab42 in com-
bination with a low dose of the aggregated Ab42 peptide
in the absence of adjuvants. The rationale for this com-
bined vaccination approach is to provide an aggregated
Ab42 peptide nucleus for the plasmid DNA encoded Ab42
peptide and to boost the primary immune response raised
by the ectopically expressed peptide. This immunization
leads to a rapid generation of Ab42 peptide specific an-
tibody titers detectable after dilution of up to 1:1.000
within 2 weeks, which can be increased by further in-
oculations. One antibody recognized the aminoterminal
sequence DAEF and differs from other known antibodies.
This mouse was used for preparation of monoclonal an-
tibodies. Using sera and monoclonal antibodies for pas-
sive immunization we demonstrate solubilization of
preformed aggregates of Ab42 in vitro, staining of pla-
ques in brain sections, and lysis of plaques in vivo of
transgenic APP mice. Thus we describe a novel type of
DNA peptide vaccine for active immunization which
may be better tolerated when applied to patients than the
peptide only vaccine, which recently failed in patients.
Furthermore we describe a passive immunization which
may lead to new insights on disease mechanism and a
therapy of AD.
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Material and methods
Plasmids
For the construction of pVR1012tPA-Ab42, the coding sequence of
Ab42 was amplified by PCR and cloned into the expression vector
pVR1012-tPA [28] using the restriction sites NheI and BamI. The
construction of pVR1012-muIL-12 and pVR1012 granulocyte-
macrophage colony-stimulating factor (GM-CSF) have been de-
scribed earlier [29]. Large-scale preparation of plasmid DNA was
performed as previously described [29].
Peptides
For immunization, Ab42 peptide [1] (Bachem, Bubendorf, Switzer-
land) was dissolved in PBS and aggregated by incubation on a
shaker for 48 h at 37C at a concentration of 10 mg/ml. For in-
tramuscular injection, aggregated Ab42 peptide was suspended in
PBS to a concentration of 2 mg/ml.
Cell cultures
COS7 cells were cultured in Dulbecco’s modified Eagle’s medium
containing 10% fetal calf serum, 2 mM glutamic acid, and peni-
cillin/streptomycin. Cells were transfected with pVR1012 control
vector or pVR1012tPA-Ab42 using the calcium phosphate method
[30]. At 72 h posttransfection the cells were subjected to immu-
nofluorescence analysis using the monoclonal antibody 6H1
(Evotec Neurosciences, Hamburg, Germany) for detection of hu-
man Ab.
Active immunization
For active immunization wild-type mice from SWE breeding were
used at 4–6 weeks of age. DNA (200 g in 200 l PBS) was
injected intramuscularly into both hind legs. Where indicated, Ab42
encoding DNA was injected in combination with 100 g DNA
encoding either interleukin (IL) 12 or GM-CSF (total volume
200 l PBS). For peptide immunization mice were injected into
both hind legs with 20 g Ab42 peptide in 200 l PBS without
adjuvant. All mice were immunized at 4-week intervals for up to 12
immunizations. Blood samples were taken 2 days after every vac-
cination. For control purposes vaccinations were performed with
DNA or peptide only.
Passive immunization
Tg(huAPP695.SWE; SwAPP) mice at 16–20 months of age were
passively immunized with 200–300 l undiluted sera collected from
mice that had been actively immunized as indicated. SwAPP mice
were injected four times every 3–4 days, killed 24 h after the last
immunization, and analyzed by immunohistochemical staining or
ELISA [7]. SwAPP mice receiving sera from mice immunized with
DNA peptide combinations were treated once for 1 day or twice at
2-days intervals and killed 1 day later.
Quantification of Ab42 in brain lysates
For quantification of sodium dodecyl sulfate (SDS) soluble Ab
brain tissue was homogenized in lysis buffer containing 2% SDS,
1% Triton X-100, 20 mM Tris (pH 7.6), 137 mM NaCl, and 1
complete proteinase inhibitor mixture (Roche Molecular Bio-
chemicals, Basel, Switzerland) [7]. Cleared lysates were collected
following centrifugation at 25,000 g for 30 min at 4C. The con-
centration of Ab42 peptide in each sample was determined by
ELISA (Innogenics, Switzerland) according to the provider’s in-
structions. Statistical significance of the antibody titers raised
against the Ab42 peptide was determined by Student’s t test.
Ab42 ELISA for serum antibodies
Antibodies specific for the Ab42 peptide were detected and quan-
tified by ELISA using disaggregated Ab42 peptide as described
[31].
Thioflavin T binding assay
The disaggregation capacity of mouse sera and monoclonal anti-
bodies in vitro was determined by the amount of thioflavin T
binding to b-sheets using the thioflavin T-binding assay or ELISA
as described [6, 12]. Statistical significance of the solubilization
capacity of individual antibody clones was determined by Student’s
t test.
Generation of Ab42-specific monoclonal antibodes
Spleen cells of mouse 697 were fused with myeloma NS-1 cells for
generation of monoclonal antibodies as described [32]. Hybridoma
cells producing antibodies specific for Ab42 peptide were identified
by Ab42 ELISA. Five clones were subjected to subcloning and
grown to mass cultures. The antibodies were purified by affinity
chromatography before immunohistochemical use.
Epitope mapping
For epitope mapping 13mer peptides with two amino acid overlaps
spanning the Ab42 sequence were synthezised using SPOT syn-
thesis and immobilized on filters or glass chips using 0.3–0.6 mol
per spot at Jerini AG, Berlin [33]. The peptide supports were in-
cubated with sera at 1:1.000 dilution as described [34]. Peptide
bound antibodies were detected using a peroxidase-labeled anti-
mouse IgG polyclonal antibody together with a chemiluminescent
substrate and the LumiImager (Roche Diagnostics, Mannheim,
Germany).
Immunohistochemistry
Sera from actively immunized wild-type mice were diluted 1:10,
1:100, and 1:1.000 in PBS and used for detection of amyloid pla-
ques in paraffin embedded brain sections of a 12 months old
transgenic SwAPP mouse. The monoclonal antibody 4G8 (1:1.000
diluted; Signet Pathology Systems, Dedham, Mass., USA) was used
as the positive control. To determine the number of amyloid pla-
ques of passively immunized mice, coronal brain sections (5 m)
were immunostained with the antibody 4G8 (dilution 1:1.000) and
plaque burden was estimated in five individual sections of each
animal.
Results
Cloning and expression of Ab42
The plasmid comprises the human cDNA coding for the
Ab42 fused to the tissue-type plasminogen activator (tPA)
secretory signal under the control of the cytomegalovi-
rus – immediate early enhancer/promoter region and
the pVR1012 backbone (Fig. 1a). Expression of Ab42 was
verified by immunofluorescence staining with the anti-
body 6H1 in transiently transfected COS7 cells (Fig. 1b)
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and quantified by ELISA for the expression of human
Ab42. The amount of Ab42 secreted into the culture su-
pernatant was 1.9 pg per 105 cells in 48 h. The cell lysate
contained 24 pg Ab42 per 105 cells.
Immunization and antibody titers
For active immunization DNA coding for Ab42 was
used in combination with aggregated Ab42. Immuniza-
tions were performed by intramuscular injection of DNA
(200 g) and peptide (20 g) or as indicated in the indi-
vidual experiments. No adjuvant was used. This is in con-
trast to previous peptide vaccinations, where much high-
er amounts of peptide were administered combined with
Freund’s complete adjuvant, phage coupled to bovine
serum albumin or liposomes [6, 10, 20]. Antibody titers
determined by ELISA showed that the combination of
DNA and peptide vaccination described here resulted in
detectable antibody titers at a dilution of 1:1.000 after
only one immunization (Fig. 2a). The observed increase
in antibody titers specific for Ab42 was significant 6
(P<0.098), 8 (P<0.02) and 10 weeks (P<0.00001) after
the initial injection compared to the control vaccination
with empty backbone DNA (Fig. 2a). The DNA peptide
vaccination induced higher titers up to 1:10.000 after four
to eight injections (P<0.016 and P<0.088, respectively,
compared to vaccination with empty vector DNA), which
further increased with more immunizations (Fig. 2b).
Combination of Ab42-encoding DNA with DNA encoding
IL-12 (data not shown) or GM-CSF without peptide in-
duced very low antibody titers (Fig. 2b). Control experi-
ments showed that the peptide alone gave a weak and
transient response. Empty backbone DNA control and
DNA encoding Ab42 alone were both negative. The com-
bination of backbone DNA and peptide, however, gave
rise to significant Ab42-specific antibody titers, 8 and
10 weeks after the first vaccination (P<0.0279, and
P<0.0043, respectively). This may be attributable to CpG
sequences in the DNA backbone (Fig. 2a, open circles)
[35].
In vitro lysis of aggregates by thioflavin binding assay
To determine the ability of antibodies to dissolve Ab
peptide aggregates in vitro we aggregated Ab42 by incu-
bation at 37C for 7 days without agitation [3]. This ag-
gregate binds the fluorescent dye thioflavin T and allows
determination of the degree of solubilization, measured
either by ELISA of released solubilized Ab peptides or as
a shift of absorbance and emission from 380 and 430 nm
to 450 and 480 nm of thioflavin bound to Ab aggregates,
respectively. Figure 3a shows one of three independent
experiments in which mouse sera were tested by ELISA
whereby mouse 697 exhibited the strongest disaggrega-
tion capacity in vitro. It was vaccinated with a combi-
nation of Ab-encoding DNA and peptide. Monoclonal
antibodies were generated from this mouse, concentrated
50-fold from hybridoma supernatants and tested for their
disaggregation capacity using the thioflavin binding as-
say (Fig. 3b). The clones 16E6H9 (P<0.0024), 14E6C9,
(P<0.015), and 16G1F12, (P<0.015) showing significant
solubilization of aggregated Ab42 were selected for fur-
ther subcloning.
Epitope mapping of antisera
The sera obtained were analyzed for their ability to bind
to linear peptides derived from Ab42. Sixteen consecutive
peptides 13 amino acids in length with two amino acids
overlaps were spotted onto filter paper. Binding was
quantified by chemiluminescence (Fig. 4) [33]. Serum
Fig. 1 a The plasmid DNA coding for Ab42 contains the secretory
signal sequence of tissue-type plasminogen activator (tPA), the
cytomegalovirus (CMV) promoter PCMV, and the Kanamycin re-
sistance gene KanR. VR1012 indicates the plasmid backbone. b
COS7 cells were transfected with the plasmid pVR1012tPA-Ab42
and analyzed for Ab42 protein expression by immunofluorescence
analysis using the antibody 6H1. Of Ab42 peptide 24 pg is ex-
pressed in 105 cells and 1.9 pg in the supernatant of 105 cells
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from mouse 697 preferentially bound to the very N-ter-
minal region of the Ab peptide comprising the amino acid
sequence DAEF. A second serum from mouse 702, which
received DNA encoding Ab only, showed a much re-
duced binding by about tenfold with no preference for any
sequence. Antibodies obtained from mice 707 or 709,
which received DNA encoding Ab plus DNA encoding
GM-CSF or IL-12, showed low binding to all or to central
epitopes, respectively.
Reactivity of sera with amyloid plaques
Frontal brain sections from a 12 months old mouse
transgenic for human APP (tgHuAPP695SWE) [5] were
incubated with antisera at dilutions from 1:10 to 1:1.000
obtained from actively immunized mice and were com-
pared to a commercially available control antibody 4G8.
Six sera were tested using five slices for each (Fig. 5a).
The results show that the serum of mouse 697, which
was immunized with the Ab-encoding DNA and peptide
combination, stained the plaques at a dilution of 1:100
(Fig. 5a, C). Mice immunized with DNA encoding Ab42
and DNA encoding GM-CSF (mouse 707) or IL-12
(mouse 709) showed staining of neurons only (Fig. 5a, F)
or no staining at all (Fig. 5a, G), respectively. Sera of all
other mice were negative for staining. Antiserum from
mouse 3583, which was immunized by peptide and con-
trol vector, gave rise to staining of plaques (Fig. 5a, H).
Two monoclonal antibodies derived from mouse 697,
16G1, and 16E6, harvested from hybridoma supernatants,
both containing 42.5 mg/ml, allowed staining of plaques
at a dilution of 1:1000, whereby 16E6 was specific for
plaques and 16G1 also recognized APP (Fig. 5a, I, K).
Plaque reduction in vivo by passive immunization
For passive immunization transgenic mice at the age of
16–20 months received antisera from mice vaccinated
with the Ab-DNA peptide combination, DNA encoding
Ab42 alone, DNA encoding Ab42 combined with DNA
encoding IL-12, GM-CSF, or only empty backbone as
control DNA. A quantity of 250–300 l of the sera was
injected into the tail veins. Serum of mouse 697, vacci-
nated with the Ab-DNA peptide combination, was in-
jected once (300 l) in one mouse, which was killed 1 day
Fig. 3 Disaggregation tested by ELISA for solubilized Ab com-
plexed with antibodies. Ab peptide was aggregated on microtiter
plates (7 days) and treated with antibodies. The solubilized Ab as
immune complex was determined by ELISA measuring the ab-
sorbance at 405 nm (a). Alternatively, 50-fold concentrated hy-
bridoma supernatant was added and the amount of thioflavin bound
to b-sheets in the lysate measured by fluorescence. Seven of 16
clones are shown. Error bars Standard deviation of three mea-
surements (b)
Fig. 2 Antibody titers. aMice were immunized with plasmid DNA
encoding Ab42 and the analogous peptide at the indicated time
points (arrows). The vaccination was performed with three to four
mice per group. The titers were determined by ELISA with mo-
nomeric Ab peptide. Filled circles Ab encoding DNA and Ab
peptide combined; open circles pVR1012 backbone DNA and Ab
peptide; X pVR1012 backbone DNA alone; filled triangles Ab
encoding DNA alone; filled squares Ab peptide alone (all three
baselines); dotted line is from the serum of a mouse immunized
with Ab-DNA peptide combination diluted 1:105, all others from
sera diluted 1:103. b Vaccination was performed in two indepen-
dent experiments using three mice per group with injections as
indicated. Results were combined. Dilution was 1:103. Filled cir-
cles Ab encoding DNA and Ab peptide combined; X pVR1012
backbone DNA; filled triangles Ab encoding DNA alone; filled
squares Ab peptide alone (all three baselines); filled diamonds Ab
encoding DNA and GM-CSF encoding DNA combined. Some in-
dividual mice that received 11 or 12 immunizations are shown with
titers 1:105 (right)
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later. Another mouse was injected twice within 3 days and
killed 1 day later. Six brain sections of each immunized
mouse were taken throughout the cortex and hippocampus
and stained with the control mAb 4G8. The number of
plaques was evaluated by microscopy and compared to
those of untreated mice. As can be seen in Fig. 5b, the
amyloid plaque burden was low 24 h after a single in-
jection (Fig. 5b, C). With two injections within 4 days no
plaques were detected (Fig. 5b, D). Sera from the other
mice showed no reduction in plaques (Fig. 5b, E–H).
As an alternative for analyzing brain sections of aged
transgenic mice younger mice at about 5 months of age
were passively vaccinated and the levels of Ab42 in SDS
extracts of brains were determined by ELISA [7]. Passive
immunization with two of the monoclonal antibodies
(clones 16E6 lanes 5–8 and 16G1 lanes 9–13) showed a
significant reduction in brain levels of Ab42 (Fig. 5c).
Lanes 1–4 show untreated control (lanes 3 and 5 failed).
In addition to the evaluation of plaque reduction in the
brains of human APP transgenic (tgHuAPP695SWE) mice
by passive immunization, we also wished to test the com-
bined DNA vaccine Ab42 peptide active immunization
protocol. However, the overexpression of the human APP
protein in transgenic (HuAPP695.SWE) mice leads to an
increased spontaneous mortality in an age-dependent man-
ner. Under standard laboratory conditions only approx.
50% of the animals reach an age of 1 year. Unfortunately,
too many of the heterocygotic APP transgenic mice died
during the study to allow a meaningful interpretation of
the results. However, the observed mortality rate of mice
actively immunized with DNA, peptide, or a combination
of the two was not increased when compared to untreated
control animals (data not shown).
Discussion
Vaccination against the amyloid Ab protein is of high
interest. Here we describe a vaccination procedure using
plasmid DNA combined with peptides. A few injections
were sufficient to raise relevant antibody titers in all eight
mice. The titers increased with the number of inocula-
tions. DNA as a vaccine has been applied in many pre-
clinical as well as clinical settings and proved to be ex-
tremely safe but of rather low efficiency [36]. The com-
bination of DNA with peptide boosts increased the effi-
ciency, by which both the humoral and the cellular im-
mune response were involved. DNA prime peptide boost
regimens are about to enter clinical trials as vaccines
against various pathogens such as human immunodefi-
ciency virus and Ebola virus. A long-term follow-up study
in patients has not shown any signs of anti-DNA anti-
bodies as a risk for autoimmune diseases and was well
tolerated without any side effects [37].
Peptide vaccines have been tested previously in com-
bination with Freund’s adjuvant, liposomes, phages and
by different routes [6, 10, 20, 21]. In most previous tests
50–100 g of peptide per injection was used. Recently
patients with progressed AD were treated with amyloid
Ab peptide vaccines in a clinical trial. It resulted in the
occurrence of meningoencephalitis in some of the patients
and led to a halt of the clinical trial [22, 31]. The DNA
construct combined with the aggregated Ab peptide used
here induced antibodies that specifically recognized the
very aminoterminal four amino acids DAEF of the amy-
loid Ab peptide. The serum when injected intravenously
for passive immunization of SwAPP transgenic mice 16–
20 months old induced a rapid reduction in plaques within
24 h after treatment.
Passive immunizations have been described in trans-
genic mice with m266 (recognizing N-terminal se-
quences) [14, 15, 16] and monoclonal antibodies 3D6 and
10D5 (recognizing N-terminal sequences) [18]. They bind
to Ab plaques and some lead to reduction of plaque
burden (for review see [38]). m266 reversed memory
defects in learning and recognition tasks [16]. The mono-
clonal antibodies described here were derived from the
mouse 697, which produced serum against DAEF, and
differ from sera previously described. Reduction in the
amount of Ab in the brains of young (5 months of age)
and amyloid plaques of old (16–20 months of age) AD
mice was observed here. The reduction was very rapid
and occurred within 24 h after a single injection of 200–
300 l undiluted sera. A rapid biological response has
previously been reported and was attributed to Fc-medi-
Fig. 4 Peptide scanning. Sixteen consecutive peptides, 13 amino
acids in length, which overlapped by 11 amino acids with both
neighboring peptides, were synthesized, spotted onto membranes,
and analyzed with the sera indicated for recognition of epitopes.
Mouse 697, which recognized the aminoterminal sequence DAEF,
was used for preparation of monoclonal antibodies
711
Fig. 5 a Immunohistochemical staining of amyloid plaques in
brains of 12 months old transgenic APP mice by sera of immunized
mice. Monoclonal antibody 4G8 served as positive (A), the sec-
ondary antibody as negative control (B). Sera were tested at the
dilutions indicated. Serum of mouse 697 immunized with Ab DNA
and peptide (C), mice 684/686 empty vector control (D, E), mouse
707 Ab DNA and GM-CSF DNA (F), mouse 709 Ab DNA and
IL-12 DNA (G), mouse 3583 backbone DNA and peptide (H).
Purified monoclonal antibodies (mAb;)diluted to the final con-
centration of 42.5 g/ml) derived from mouse 697 are 16G1 (I) and
16E6 (K). b Passive immunization of 16–20 months old transgenic
Ab mice. Sera from mice immunized with various combinations of
DNA and/or peptide were injected into the tail vein of transgenic
mice. The mice were killed, and the brain sections were stained
with 4G8 positive control antibody (diluted 1:1.000) (A). The
secondary antibody control is shown in B. For passive immuniza-
tion serum obtained from mouse 697, vaccinated with Ab DNA and
peptide, was injected once (C) or twice at 2-day intervals (D) and
analyzed 1 day later by mAb 4G8. Six slices of each brain were
tested with similar results; only one is shown. Other sera for passive
immunizations were from mice immunized six to eight times with a
combination of Ab DNA and GM-CSF DNA (serum of mouse 707,
E, F), Ab DNA alone (serum of mouse 702, G), Ab DNA and IL-12
DNA (serum of mouse 709, H). c Ab42 Contents in brain lysates of
passively immunized mice. Transgenic mice 5–6 months old were
treated intravenously with purified antibodies from hybridoma su-
pernatants 4 times at 4-day intervals (250 g in 200 l per injec-
tion). The mice were then killed and Ab aggregates analyzed from
brain homogenates by ELISA. Mice 1–4 received buffer, mice 5–8
were passively immunized with the monoclonal antibody 16E6, and
mice 9–13 with 16G1. Mice 3 and 5 were drop-outs
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ated phagocytosis of microglial cells [18]. The alternative
theory of a “peripheral sink” has also been proposed,
whereby the formation of antigen-antibody complexes in
the periphery sequesters Ab peptides and prevents the
deposition of new plaques. Alternatively, plaques may be
physically disrupted by the antibody. The short time pe-
riod required for disruption of plaques may be due to
physical or conformational changes in the plaques in-
duced by the antibody. A monoclonal antibody of this
kind has been described for the scrapie prion PrPsc by
Prusiner and colleages [39]. However, passive immuni-
zation has recently been performed in APP23 transgenic
mice with 20 weekly injections of 500 g monoclonal
antibody that recognizes amino acids 3–6. After 5 months
the mice developed cerebral hemorrhages, presumably
due to the weakening of amyloidotic vessel walls by local
inflammatory reactions [40].
The effect of empty DNA plasmid controls combined
with the Ab peptide was unexpected since the antibody
titer and specificity resembles that with Ab DNA. It may
be possible to use only CpG oligonucleotides with the Ab
peptide for clinical use.
In summary, we present two new aspects, a new active
immunization procedure with a Ab-DNA peptide com-
bination and a new monoclonal antibody for passive im-
munization. The combined DNA peptide vaccine differs
significantly from all previous ones since no adjuvant was
used and the amount of peptide used, 20 g, per injection
was very low. This is important in view of the suspicion
that the use of adjuvants may support a Th1-mediated
immune response, which has been implicated in autoim-
mune diseases and may have contributed to the adverse
response in some patients vaccinated with the Ab42 pep-
tide. Moreover, analysis of the Ig subtype of the Ab42
peptide-specific monoclonal antibodies, revealed that all
of them were of the IgG1 subtype. This finding indicates
that the combined DNA vaccine/Ab42 peptide vaccination
approach induces a Th2 type of response, which may be
an important advantage by inhibiting an autoimmune re-
action in patients. A few injections of the DNA peptide
combination gave rise to significant antibody titers which
could be increased by additional boosts. Furthermore, a
monoclonal antibody may be useful for characterization
of molecular mechanisms underlying the rapid solubili-
zation of plaques in vivo and in vitro and may be de-
veloped into a therapeutic vaccine applied at early stages
of AD to prevent disease progression.
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